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Most children with immune thrombocytopenia (ITP) will have spontaneous remission
regardless of therapy, while about 20% will go on to have chronic ITP. In those children
with chronic ITP who need treatment, standard therapies for acute ITP may have adverse
effects that complicate their long-term use. Thus, alternative treatment options are
needed for children with chronic ITP. Thrombopoietin receptor agonists (TPO-RA) have
been shown to be safe and efficacious in adults with ITP, and represent a new treatment
option for children with chronic ITP. One TPO-RA, eltrombopag, is now approved for
children. Clinical trials in children are ongoing and data are emerging on safety and
efficacy. This review will focus on the physiology of TPO-RA, their clinical use in children,
as well as the long-term safety issues that need to be considered when using these
agents.
Keywords: immune thrombocytopenia, chronic immune thrombocytopenia, thrombopoietin receptor agonists,
eltrombopag, romiplostim
Introduction
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder that affects both children and
adults, resulting in isolated platelet counts <100 109/L and potentially life-threatening bleeding.
ITP is generally the result of increased platelet destruction and decreased platelet production leading
to thrombocytopenia. IgG antibodies bind to platelet membrane glycoproteins, typically GPIIb/IIIa,
GPIb/IX, or GPIa/IIa, causing phagocytosis by the reticuloendothelial system in the liver and spleen,
resulting in early clearance, and hence a decreased platelet life span (1). Impaired production of
platelets also contributes to ITP. The antibodies bind to the surface of megakaryocytes (which
express the same glycoproteins) in the bone marrow leading to destruction of megakaryocytes and
decreased platelet production (2). ITP is a diagnosis of exclusion and is either primary or secondary.
Primary ITP occurs in the absence of any inciting cause. Secondary ITP is caused by an underlying
disease or drug exposure. ITP is also classified based on duration. Patients have newly diagnosed ITP
in the first 0–3months, persistent ITP in the 3- to 12-month period, and chronic ITP at >12months.
ITP may also be classified on severity, which is determined based on the presence or absence of
bleeding symptoms (3).
Approximately 80% of pediatric patients will respond to a single treatment or combination of
first line therapies, which include watchful waiting, corticosteroids, IVIG, or anti-D (4, 5). For the
remaining patients, additional second line treatments are needed. These generally include further
immune suppression, for example, with anti-CD20 (rituximab), with the goal of decreasing the
production of anti-platelet antibodies. Splenectomy is avoided in young children both because of
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the risk of bacterial sepsis and because children have a high rate of
spontaneous resolution of ITP. A recently developed class of drug,
whichwill be the focus of this review, is the thrombopoietin recep-
tor agonists (TPO-RA). These agents target the megakaryocytes
and drive them to increased platelet production.
Thrombopoietin Receptor Agonists
Thrombopoietin (TPO) is a growth factor produced primarily
by the liver that mediates its effects through the TPO receptor
(cMPL). It is the most important growth factor for platelet pro-
duction (6, 7). TPO binding to the cMPL receptor results in acti-
vation of the STAT and MAPK signaling pathways, and leads to
megakaryocyte differentiation and growth. Its circulating concen-
tration is regulated primarily by the platelet and megakaryocyte
mass, and is usually increased when platelets are decreased, such
as in aplastic anemia. However, although platelets are decreased
in ITP patients, endogenous TPO levels have been noted to be
normal or even low in response to the platelet decrease (7, 8). This
has been attributed to the increased megakaryocyte mass seen in
the bone marrow of ITP patients.
The two first-generation TPO-RA were recombinant forms of
human TPO (9). One was a full-length TPO protein produced in
Chinese hamster ovary cells, and the other was a partial-length
protein coupled to polyethylene glycol produced in Escherichia
coli. These agents were targeted primarily at chemotherapy-
induced thrombocytopenia. They had mixed success in patients
receiving non-myeloablative chemotherapy. However, their use
was discontinued after subjects developed auto-antibodies that
cross reacted with endogenous TPO, leading to prolonged throm-
bocytopenia in some subjects.
The second generation thrombopoietic agents were designed
to have no amino acid sequence homology to endogenous TPO
and are structurally different from TPO to avoid development
of neutralizing antibodies. These agents bind to and activate the
TPO receptor, so are also TPO-RA (Figure 1) (9). Currently,
there are two FDA approved second generation agents for adults,
romiplostim and eltrombopag. As of June 11, 2015, eltrombopag
received FDA approval for use in children >6 years of age. Romi-
plostim continues to be in trials for children.
Romiplostim (AMG 531, AMP-2, Nplate) was approved in
2008 by the FDA for use in adults with ITP. It is a pepti-
body consisting of two short peptides that are coupled to an
immunoglobulin Fc domain, produced by recombinant DNA
technology in E. coli (7). The peptides have no homology to
TPO. Like TPO, romiplostim promotes megakaryocyte growth
by binding to the TPO binding site on cMPL, resulting in
activation of the STAT and MAPK signaling pathways, driving
megakaryocyte proliferation and differentiation (Figure 1) (10).
The peptides bind competitively to the TPO binding site, while
the Fc domain is essential for increased half-life of the drug.
Romiplostim is administered weekly subcutaneously at doses
of 1–10µg/kg.
Eltrombopag (SB497115, Promacta) was also approved in 2008
by the FDA for adults and 2015 for children >6 years of age
with ITP not responsive to first line therapies. It is a small
non-peptide agonist that binds to the transmembrane domain
of cMPL, rather than the TPO binding site. Eltrombopag bind-
ing results in signaling through the STAT and MAPK signal-
ing pathways, similar to the signaling mechanism of TPO, and
promotes the growth of TPO-dependent cell lines (Figure 1)
(11). Because eltrombopag does not bind to the same site of the
TPO receptor as TPO, this non-competitive binding is thought
to allow eltrombopag and TPO to have additive cell-signaling
effects. Eltrombopag is administered orally daily at doses of up
to 75mg/day.
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FIGURE 1 | Thrombopoietin receptor activation by thrombopoietin, romiplostim, and eltrombopag via the STAT/MAPK pathways for increased
platelet production. This research was originally published in International Journal of Hematology [Kuter (9) by The Japanese Society of Hematology].
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Experience in Pediatrics
Romiplostim
In 2011, Bussel et al. reported the first multicenter phase I–II
randomized double-blind study of the use of a TPO-RA, romi-
plostim, in order to determine both safety and efficacy in children
(12). The study enrolled 22 children aged 1–18 who had been
diagnosed with ITP at least 6months prior. Seventeen patients
received romiplostim, starting at a dose of 1µg/kg/week and
escalated to 10µg/kg/week, and five received placebo weekly for
12weeks, with a platelet goal of 50–250 109/L. To maintain this
goal, the weekly median dose at 12weeks was 5µg/kg. Eighty-
eight percent of patients achieved a platelet count50 109/L for
two consecutive weeks, while patients in the placebo group had no
effect. Platelet counts 50 109/L were maintained for a median
of 7weeks in romiplostim patients and 0week in placebo patients.
In this group of patients, the most commonly reported adverse
events were headache and epistaxis, and there were no serious
adverse events.
That same year Elalfy et al., in Egypt, published a random-
ized placebo-controlled study of romiplostim in 18 children
aged 2.5–6 years of age with chronic poorly responsive ITP (13).
These patients had a median baseline count of 10.5 109/L and
were randomized (2:1) to receive romiplostim or placebo for
12weeks. Romiplostim dosing began at 1µg/kg/week and esca-
lated to 5µg/kg/week. The median weekly dose of romiplostim
was 2µg/kg. The platelet count goal of 50 109/L was reached
and maintained by 83% of patients receiving romiplostim. Fifty
percent of patients reported at least one adverse event including
headache, epistaxis, vomiting, and coughing, but there were no
serious adverse events.
The following year a prospective study, also from Egypt, by
Mokhtar et al., described romiplostim therapy in eight non-
splenectomized children aged 3.4–15.2 years with unresponsive
chronic ITP, although one patient was initially excluded because
of grade 3 bone marrow reticulin (14). These children had ITP
lasting 13months to 7.3 years with a median of 2.4 years. Romi-
plostim dosing was initiated at 1µg/kg/week and escalated by
1µg/kg/weekwith a platelet count goal>50 109/L. The duration
of therapy varied between 1 and 22weeks. Fifty-seven percent of
patients demonstrated variable responses but then showed a rapid
increase in platelet count when pulse steroid therapy was added.
Adverse events were mild and transient.
In 2012, a general hospital in Madrid, Spain published a ret-
rospective, longitudinal observational study of three pediatric
patients refractory to treatment who were treated with romi-
plostim (15). Among the three patients, one was newly diagnosed
and two had chronic ITP. These patients were started at a dose
of 1µg/kg/week and escalated up to 10µg/kg/week. They were
followed for 27–39weeks. Responses were seen in 7–28 days, and
were maintained for 37–91% of visits. The adverse events were
headache and asthenia in one patient and mucocutaneous bleed-
ing in another patient after stopping romiplostim. There were no
serious adverse events.
In 2014, a retrospective national study in France from the
CEREVANCE group, evaluated the use of romiplostim in 10
children aged 1–18 with non-responsive or refractory chronic
ITP (16). Patients started romiplostim at an initial dose of
1µg/kg/week and escalated up to 10µg/kg/week with a platelet
count goal of at least 50 109/L. Median dose was between 4 and
10µg/kg/week. The median duration of treatment was 9months
(range 3–36). Five children improved clinically andhad disappear-
ance of mucosal bleeding. The other five patients had no response
and had persistent severe bleeding. Six children reported adverse
events including local pain, headache, asthenia, abdominal pain,
and one mood disorder, but no serious adverse events were seen.
In 2014, Seidel et al. in Austria described their center’s experi-
ence with romiplostim in treating seven patients between the ages
of 2 and 17 with chronic ITP (17). These patients were started
on a dose of 2–5µg/kg/week and escalated to 10µg/kg/week.
Response rates were variable, but patients were noted to have
increased platelet counts when combined with either IVIG, anti-
D, mycophenolate mofetil, or rapamycin. This group reported no
adverse events and had normal bone marrow evaluations.
Also, in 2014, Ramaswamy et al. published a retrospective anal-
ysis of 33 children aged 19months to 19 years with ITP >6months
who received either romiplostim or eltrombopag (18). Of those 33
children, 21 received romiplostim and 12 received eltrombopag.
The median starting dose was 5.0µg/kg/week for romiplostim
and 50mg daily for eltrombopag. The mean maximum dose of
romiplostimwas 8.1µg/kg/week and 75mgdaily for eltrombopag.
Twenty-seven (82%) patients responded to TPO-RA, 18 of 21 to
romiplostim, and 9 of 12 to eltrombopag. These 27 patients had
platelet counts 50 109/L and 20 109/L above baseline for
2 consecutive weeks; 26 had 50% of platelet counts 50 109/L.
Duration of romiplostim use ranged from 6 to 44months (11/18
ongoing) and of eltrombopag 23 to 53months (7/12 ongoing).
One patient on eltrombopag experienced a deep-vein thrombosis
at the site of and ankle fracture but no other serious adverse events
occurred. Among 24 bonemarrows performed, 10were aftermore
than 2 years of therapy, 23 were normal and 1 was MF-2.
Most recently, in 2015, Bussel et al. published the results for the
long-term use of romiplostim in children <18 years of age with
chronic ITP (19). This patient cohort had completed the romi-
plostim phase I–II study. Twenty patients from the cohort con-
tinued on romiplostim for up to 109weeks. All of them achieved
platelet counts >50 109/L. A subset of these, 12 patients, con-
tinued in a second extension study for up to 127 weeks. Overall,
in this cohort, treatment duration reached a median of 167weeks
and the median dose was 5.4µg/kg.
Overall, these studies have indicated that romiplostim has both
good efficacy and safety in childrenwith persistent or chronic ITP.
The response rate has been 50–88%, similar to that seen in adults.
The effective dosing is also similar to that seen in adults. Safety
data have accumulated for several years of treatment and the side
effects have been minor.
Eltrombopag
Thus far, there are fewer published studies on the use of eltrom-
bopag in children. However, at the 56th annual 2014 Ameri-
can Society of Hematology meeting, pooled data were presented
from two studies (1450 PETIT and PETIT2) of children aged 1
to <18. Both of these studies were randomized, double-blind,
and placebo-controlled study. Patients were randomized 2:1 to
eltrombopag or placebo. After the placebo-controlled random-
ized phase, patients were eligible to complete 17 or 24weeks of
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treatment with eltrombopag. Dose was adjusted based on platelet
counts to a maximum of 75mg daily.
A total of 174 subjects were enrolled in both studies. One
hundred fifty-nine patients were randomized and 157 received
1 dose of randomized study treatment. During the randomized
period 62% of children on eltrombopag versus 24% of children
on placebo achieved a response with platelet counts 50 109/L
at least once between 1 and 6weeks. At each week, a higher pro-
portion of the eltrombopag group had a response versus placebo
group. Thirteen percent of children on eltrombopag received
rescue treatment compared to 31% of children on placebo. During
the extension study, sustained reduction or discontinuation of
baseline ITP medications was achieved by 50% of patients; 81%
of patients had a platelet count response at least once; 52% had
a platelet count response for 50% of assessments; and 38%
responded for 75% of assessments. For weeks 13–24, 47% of
subjects achieved responses.
The most common AEs were headache, upper respiratory tract
infection, and nasopharyngitis. Serious AEs were reported in 8%
of eltrombopag group versus 12% of placebo group. In the ran-
domized period, an ALT elevation of three times ULN occurred in
five patients receiving eltrombopag andnone in the placebo group.
In the extension study, there were an additional seven patients
with ALT elevation to three times ULN. All ALT abnormalities
resolved either while still on treatment or at discontinuation. No
thromboembolic events were reported. Cataracts occurred in two
patients; both had used corticosteroids and one had pre-existing
cataracts.
These two large placebo-controlled studies indicate that eltrom-
bopag has both good efficacy and a good safety profile in children,
which led to its approval for children >6 years of age this year.
Elevation of ALT was noted as an AE in some patients on the
treatment arm. This distinguishes eltrombopag from romiplostim,
which has not been reported to be associated with increased liver
enzymes. The occurrence of cataracts in two study subjects is also
unique to eltrombopag. Therefore, these potential AEs should be
monitored when using eltrombopag.
TPO-RA in Other Thrombocytopenias
TPO-RA have also been used for other causes of thrombocytope-
nia. Currently, eltrombopag is FDA approved for the treatment
of thrombocytopenia in chronic Hepatitis C, and most recently
received approval for the treatment of severe aplastic anemia.
Eltrombopag has also been reported to increase platelet counts
in patients with Wiskott–Aldrich syndrome and other inherited
thrombocytopenias. Romiplostim is currently in trials for the
treatment of thrombocytopenia other than ITP. Of note, while
TPO-RA are not intended to be curative therapy and platelet
counts will predictably fall after discontinuation, there have been
reports of durable remission in adults after prolonged treatment
with TPO-RA. This has yet to be reported in children.
Dosing
In adults, the typical maintenance dose of romiplostim ranges
between 3 and 8mcg/kg for a target platelet count >50 109/L
(20). In children, a similarmaintenance dose seems to be required.
Median adult dosing of eltrombopag is 50mg/day, as described in
the EXTENDdose study (21).However, in children, it appears that
higher dosing per weight may be needed but the recommended
starting dose is 50mg/day not to exceed 75mg/day. The efficacy
of both drugs is similar to those seen in adults with response rates
of 80% and higher if transient responses are included.
Safety and Monitoring
The most common side effects reported by both children
and adults for both agents include headache, nausea, and
vomiting. More significant adverse effects include arterial and
venous thromboembolic events and bone marrow reticulin
deposition/fibrosis with both agents and liver toxicity seen
with eltrombopag. Arterial and venous thromboembolic events
in adults have mostly occurred in patients with prior history
of thrombosis (22). In children, there has been one reported
thromboembolic event: one DVT in the setting of an ankle
fracture (18). Bone marrow reticulin deposition is seen in both
adults and children. In adults, approximately one-fifth of patients
will develop a grade 2/3 myelofibrosis (23). This appears to be
reversible once the TPO-RA is discontinued (22, 23). In children,
reticulin deposition occurs less frequently: Ramaswamy et al.
reported 23/24 normal bone marrows in pediatric patients, some
after years on therapy, and Seidel reported 5/5 normal marrows
after long-term use of romiplostim. Eltrombopag may cause
elevated liver enzymes. In the patients receiving eltrombopag
in the 6-week study by Bussel et al., in the RAISE study and in
the EXTEND study, 10% of treatment group patients had liver
enzyme (ALT) elevations to three times the upper limit of normal,
while 3% in the placebo group had ALT elevations (24). The ALT
returned to normal in some patients even while they continued
on eltrombopag. In other patients, the ALT returned to normal
after discontinuation of the study drug. Similar effects have been
noted in children, as described in the PETIT trials.
Prior to starting either medication, patients should have
baseline lab values for complete blood counts (CBCs) and liver
TABLE 1 | Current TPO-RA under study for use in ITP.
(a) Romiplostim and eltrombopag in children
NCT02201290 A long-term safety study of eltrombopag in pediatric patients
with chronic ITP
NCT01880047 Safety and efficacy of eltrombopag at escalated doses
NCT01957176 A rollover study to provide continued treatment with
eltrombopag
NCT01971684 Treatment decisions and outcomes in pediatric refractory ITP
NCT01071954 A study evaluating the safety and efficacy of long-term dosing
of romiplostim
NCT02279173 Single arm, open-label, long-term study of romiplostim
NCT01971684 Treatment decisions and outcomes in pediatric refractory ITP
(b) Other TPO-RA
Small molecules
NCT01438840 Avatrombopag (E5501, AKR-501, YM477, AS 1670542): oral
NCT00621894 LGD-4665: oral
N/A Totrombopag (SB-559448): oral
Recombinant human TPO
NCT02139501 TPIAO: oral, licensed in China
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function tests (AST, ALT, bilirubin), and should be monitored
regularly. They should have CBCs to assess platelet counts weekly
until a stable count is achieved and then counts can be mon-
itored monthly. For patients taking eltrombopag, LFTs should
be monitored weekly, followed by every other week during dose
adjusting, and then monthly once a stable dose has been reached.
More frequentmonitoring for any abnormality is at the physician’s
discretion. Patients on either agent should have their marrow
examined periodically for reticulin. Although there are no con-
sensus guidelines regarding frequency of monitoring the bone
marrow for reticulin deposition, the authors usually examine the
marrow annually.
Conclusion
Ultimately, the goal of therapy in ITP is to increase the
platelet count and prevent clinically significant bleeding. Thus
far, TPO-RA have demonstrated response rates in children
comparable to that of IVIG, and have been well tolerated
with minor side effects. TPO-RA represent a paradigm shift
in treatment of ITP in that they directly target a mechanism
of thrombocytopenia with few off-target effects. The TPO-RA
are not immunosuppressive and thus avoid the side effects of
traditional immunosuppressive therapies. The most concern-
ing side effects that are seen in adults, bone marrow reti-
culin deposition and thrombosis, have been less commonly
seen in children. Long-term effects remain to be determined,
but some children have already been in current clinical trials
for several years (Table 1). Thus, for children who fail first
line therapy, TPO-RA represent a novel and effective alternate
therapy.
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